| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Academic Article
|
Therapy-related myeloid leukemia.
|
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
|
Academic Article
|
High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase.
|
|
Academic Article
|
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome.
|
|
Academic Article
|
Myeloid leukemia after hematotoxins.
|
|
Academic Article
|
Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia.
|
|
Academic Article
|
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
|
|
Academic Article
|
Myeloid leukemia after cytotoxic therapy and other hematotoxins.
|
|
Academic Article
|
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
|
|
Academic Article
|
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
|
|
Academic Article
|
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
|
|
Academic Article
|
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?
|
|
Academic Article
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
|
|
Academic Article
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
|
|
Academic Article
|
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
|
|
Academic Article
|
Polymorphisms in the MLL breakpoint cluster region (BCR).
|
|
Academic Article
|
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.
|
|
Academic Article
|
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
|
|
Academic Article
|
The U.S. trials in adult acute lymphoblastic leukemia.
|
|
Academic Article
|
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
|
|
Academic Article
|
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
|
|
Academic Article
|
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
|
|
Academic Article
|
Management of acute lymphoblastic leukemia in older patients.
|
|
Academic Article
|
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
|
|
Academic Article
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
|
Academic Article
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review.
|
|
Academic Article
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
|
|
Academic Article
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Etiology and management of therapy-related myeloid leukemia.
|
|
Academic Article
|
Therapy-related myeloid leukemia.
|
|
Academic Article
|
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
|
|
Academic Article
|
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
|
|
Academic Article
|
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
|
|
Academic Article
|
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
|
|
Academic Article
|
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia.
|
|
Academic Article
|
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
|
|
Academic Article
|
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
|
|
Academic Article
|
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
|
|
Academic Article
|
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
|
|
Academic Article
|
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
|
|
Academic Article
|
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
|
|
Academic Article
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
|
|
Academic Article
|
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU.
|
|
Academic Article
|
Gemtuzumab ozogamicin: time to resurrect?
|
|
Academic Article
|
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
|
|
Academic Article
|
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
|
|
Academic Article
|
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
|
|
Academic Article
|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
|
|
Academic Article
|
Management of myelodysplastic syndromes.
|
|
Academic Article
|
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
|
|
Academic Article
|
Dental management of cancer patients receiving chemotherapy.
|
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
|
Academic Article
|
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.
|
|
Academic Article
|
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
|
|
Academic Article
|
Use of decline in D-xylose absorption to predict infection following intensive chemotherapy.
|
|
Academic Article
|
Listeriosis after 2-chlorodeoxyadenosine treatment.
|
|
Academic Article
|
Auto-SCT for AML in second remission: CALGB study 9620.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Therapy-related myeloid sarcoma with an NPM1 mutation.
|
|
Academic Article
|
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
|
|
Academic Article
|
Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
|
Academic Article
|
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
|
|
Academic Article
|
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia.
|
|
Academic Article
|
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
|
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
|
Academic Article
|
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
|
|
Academic Article
|
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
|
|
Academic Article
|
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
|
|
Academic Article
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
|
Academic Article
|
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
|
|
Academic Article
|
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
|
|
Academic Article
|
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
|
|
Academic Article
|
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
|
|
Academic Article
|
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
|
Academic Article
|
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
|
|
Academic Article
|
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
|
|
Academic Article
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
|
Academic Article
|
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
|
|
Academic Article
|
Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection.
|
|
Academic Article
|
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
|
|
Academic Article
|
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
|
|
Academic Article
|
Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host.
|
|
Academic Article
|
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
|
|
Academic Article
|
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
|
|
Academic Article
|
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
|
|
Academic Article
|
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
|
|
Academic Article
|
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
|
|
Academic Article
|
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.
|
|
Academic Article
|
Pepsi® or Coke®? Influence of acid on dasatinib absorption.
|
|
Academic Article
|
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
|
|
Academic Article
|
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.
|
|
Academic Article
|
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
|
|
Academic Article
|
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
|
|
Academic Article
|
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
|
|
Academic Article
|
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
|
|
Academic Article
|
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
|
|
Academic Article
|
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia.
|
|
Academic Article
|
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
|
|
Academic Article
|
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
|
|
Academic Article
|
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
|
Academic Article
|
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
|
|
Academic Article
|
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
|
|
Academic Article
|
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
|
|
Academic Article
|
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
|
|
Academic Article
|
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
|